论文部分内容阅读
我们对48例AMI的病人进行溶栓治疗，用国产尿激酶（UK）2．2万IU／kg加入100ml葡萄糖液内静点，12h后皮下注射肝素7500u，每12h一次，用3～5日，滴尿激酶前口服肠溶阿斯匹林0．3，以后0．3／日，3～5日后改为50～150mg／日维持，至出院。对其疗效评价，结果显示，发病至溶栓时间6h内者再通率明显高于6h以上者（P＜0．01）尿激酶剂量大，溶栓的效果好，不良反应轻，便于不能开展经皮冠脉内直接溶栓的基层医院的临床应用。
48 patients with AMI thrombolytic therapy, with domestic urokinase (UK) 22000 IU / kg added 100ml glucose intravenous injection, 12h after subcutaneous injection of heparin 7500u, once every 12h, with 3 to 5 days , Drip urokinase before oral administration of aspirin 0.3, after 0.3 / day, 3 to 5 days later changed to 50 ~ 150mg / day to discharge. The efficacy evaluation, the results showed that the incidence to the thrombolytic time within 6h recanalization rate was significantly higher than 6h (P <0.01), a large dose of urokinase, thrombolytic effect is good, mild adverse reactions, can not carry out Clinical application of percutaneous coronary thrombolysis in primary hospitals.